Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.60 |
| ▸ | BACE1 | P56817 | 6/20 | 0.60 |
| ▸ | CTSD | P07339 | 3/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.43 |
| ▸ | CTSE | P14091 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885527 | 1.00 | REN (0.60) | RENBACE1CTSDOPRM1OPRK1 | |
| SCHEMBL2884778 | 0.87 | BACE1 (0.48) | RENBACE1CTSDOPRM1OPRK1 | |
| SCHEMBL2884780 | 0.87 | BACE1 (0.48) | RENBACE1CTSDOPRM1OPRK1 | |
| SCHEMBL2885533 | 0.86 | BACE1 (0.53) | RENBACE1CTSDBACE2 | |
| SCHEMBL4142501 | 0.85 | BACE1 (0.64) | RENBACE1CTSDBACE2 | |
| SCHEMBL4141529 | 0.84 | BACE1 (0.51) | RENBACE1CTSDBACE2 | |
| SCHEMBL2890275 | 0.83 | OPRM1 (0.49) | RENBACE1CTSDOPRM1OPRK1 | |
| SCHEMBL2890273 | 0.83 | OPRM1 (0.49) | RENBACE1CTSDOPRM1OPRK1 | |
| SCHEMBL2888618 | 0.81 | BACE1 (0.66) | BACE1CTSD | |
| SCHEMBL2888615 | 0.81 | BACE1 (0.66) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461160-B2 | Dihydropyrimidinones | HOFFMANN-LA ROCHE, INC. (US) | 2013-06-11 | — | — | US | claimed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | claimed |
| US-8461160-B2 | Dihydropyrimidinones | HOFFMANN-LA ROCHE, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | BACE2, BACE1, PSEN2 | REN 40/4885BACE1 2/4885CTSD 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.